Страна: Великобритания
Език: английски
Източник: MHRA (Medicines & Healthcare Products Regulatory Agency)
Atomoxetine hydrochloride
Macleods Pharma UK Ltd
N06BA09
Atomoxetine hydrochloride
100mg
Oral capsule
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 04040000; GTIN: 18901463139117
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. Atomoxetine - Keep this leaflet. You may need to read it again. ATOMOXETINE MACLEODS 10, 18, 25, 40, 60, 80 AND 100 MG CAPSULES, HARD PACKAGE LEAFLET: INFORMATION FOR THE USER - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET : These checks are to decide if Atomoxetine Macleods is the correct medicine for you. CHECKS THAT YOUR DOCTOR WILL MAKE BEFORE YOU START TO TAKE ATOMOXETINE MACLEODS Tell your doctor or pharmacist if any of the above applies to you before starting treatment. This is because Atomoxetine Macleods can make these problems worse. Your doctor will want to monitor how the medicine affects you. - hard-to-control, repeated twitching of any parts of the body or you repeat sounds and words. - different moods than usual (mood swings) or feel very unhappy. - a history of epilepsy or have had seizures for any other reason. Atomoxetine Macleods might lead to an increase in seizure frequency. - unfriendly and angry (hostility) feelings. - aggressive feelings. - mania (feeling elated or over-excited, which causes unusual behaviour) and agitation. - psychotic symptoms including hallucinations (hearing voices or seeing things which are not there), believing things that are not true or being suspicious. - liver problems. You may need a lower dose. - cardiovascular disease or past medical history of stroke. - problems with sudden changes in your blood pressure or your heart rate. - low blood pressure. Atomoxetine Macleods can cause dizziness or fainting in people with low blood pressure. - high blood pressure. Atomoxetine M Прочетете целия документ
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Atomoxetine Macleods 100 mg capsules, hard 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each hard capsule contains atomoxetine hydrochloride equivalent to 100 mg of atomoxetine For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Capsule, hard Opaque brown cap/ opaque brown body size “1” capsules containing white to off white powder, with ‘I 29’ on body imprinted with black ink. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Atomoxetine Macleods is indicated for the treatment of Attention- Deficit/Hyperactivity Disorder (ADHD) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. Diagnosis should be made according to current DSM criteria or the guidelines in ICD. In adults, the presence of symptoms of ADHD that were pre-existing in childhood should be confirmed. Third-party corroboration is desirable and Atomoxetine Macleods should not be initiated when the verification of childhood ADHD symptoms is uncertain. Diagnosis cannot be made solely on the presence of one or more symptoms of ADHD. Based on clinical judgment, patients should have ADHD of at least moderate severity as indicated by at least moderate functional impairment in 2 or more settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual’s life. Additional information for the safe use of this product: A comprehensive treatment programme typically includes psychological, educational and social measures and is aimed at stabilising patients with a behavioural syndrome characterized by symptoms which may include chronic history of short attention span, distractibility, emotional lability, impulsivity, moderate to severe hyperactivity, minor neurological signs and abnormal EEG. Learning may or may not be impa Прочетете целия документ